Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23340298.
- Also identified by DOI 10.1158/1078-0432.CCR-12-3586 and PMC identifier 8559553.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
EGF receptor (EGFR)-specific monoclonal antibodies (mAb) display limited therapeutic efficacy in EGFR-positive solid tumors. To overcome this limitation, the significant improvement of the antibody-dependent cell-mediated cytotoxicity-mediated antitumor activity of a novel EGFR-specific mAb is described. Its potential impact on the efficacy of immunotherapy for EGFR-positive solid tumors is discussed.
Medical subject headings
- Antibodies, Monoclonal
- Antibody-Dependent Cell Cytotoxicity
- ErbB Receptors
- Neoplasms
- Protein Kinase Inhibitors